Thiopurine metabolites

Breakdown products of azathioprine measured in the blood to check the medicine is at a safe and useful level.

Also called: 6-tgn, 6tgn, tgn, 6-mmp, mmp, thiopurine levels, metabolite test

Related words tpmt therapeutic drug monitoring

Topics Monitoring

Questions people ask

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

Why might I take azathioprine or methotrexate alongside a biologic?

The 2025 BSG guideline recommends starting infliximab or adalimumab together with a thiopurine to reduce the chance of the body making antibodies against the biologic. Cochrane reviews found infliximab plus azathioprine or mercaptopurine probably works better than a thiopurine alone. Crohn's & Colitis UK also explains that methotrexate can reduce these antibodies.

Sources

Why do I need a TPMT blood test before azathioprine or mercaptopurine?

TPMT is an enzyme that helps the body break down azathioprine and mercaptopurine. People with low or no TPMT activity can have serious side effects on the bone marrow. NICE says TPMT should be checked before these medicines are offered, and that they should not be given if activity is deficient. Crohn's & Colitis UK explains your team may adjust your treatment or choose a different medicine based on the result. A recent blood transfusion can affect the result.

Sources

Where to read more

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease

Frontline Gastroenterology (via PMC) Guide Nov 2025 For professionals

A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.

Topics Medicines Surgery Monitoring

Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity

Crohn's disease: management (NG129)

NICE Guideline May 2019 For professionals

NICE's guideline for the NHS in England on managing Crohn's in children, young people and adults. It covers giving people information and support, treatment to bring Crohn's under control and keep it there, surgery, keeping remission after surgery, checking bone health, and pregnancy. It is about care after diagnosis rather than how Crohn's is diagnosed.

Topics About Crohn's disease Medicines Surgery Monitoring Pregnancy and fertility Children and young people Steroids Immunosuppressants

Jargon explained remission inducing remission maintaining remission osteopenia NICE guideline induce remission maintain remission glucocorticosteroid thiopurine TPMT resection stricture

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

Azathioprine: a medicine to treat autoimmune conditions

NHS Web page Oct 2026 For patients

NHS medicine guide to azathioprine. It lists skin becoming more sensitive to sunlight as a common side effect, says it may not suit people recently given a live vaccine such as chickenpox or yellow fever, and says it can be used in pregnancy if a specialist recommends it, pointing to the Bumps website for more.

Topics Immunosuppressants Cancer risk and screening Pregnancy and fertility Medicines

Jargon explained azathioprine thiopurine live vaccine immunosuppressant DMARD bone marrow

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Cochrane Systematic review Oct 2015 Patients and professionals

Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.

Topics Immunosuppressants Research

Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

Cochrane Systematic review Aug 2019 Patients and professionals

Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.

Topics Immunosuppressants Surgery Research

Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF

Search everything for "thiopurine metabolites"